BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19147825)

  • 21. The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model.
    Machado I; Mayordomo-Aranda E; Giner F; Llombart-Bosch A
    Fetal Pediatr Pathol; 2015; 34(5):271-81. PubMed ID: 26125949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry.
    Wachtel M; Runge T; Leuschner I; Stegmaier S; Koscielniak E; Treuner J; Odermatt B; Behnke S; Niggli FK; Schäfer BW
    J Clin Oncol; 2006 Feb; 24(5):816-22. PubMed ID: 16391296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases.
    Gil-Benso R; López-Ginés C; Carda C; López-Guerrero JA; Ferrer J; Pellín-Pérez A; Llombart-Bosch A
    Cancer Genet Cytogenet; 2003 Jul; 144(2):125-33. PubMed ID: 12850375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.
    Zin A; Bertorelle R; Dall'Igna P; Manzitti C; Gambini C; Bisogno G; Rosolen A; Alaggio R
    Am J Surg Pathol; 2014 Feb; 38(2):273-8. PubMed ID: 24418861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence of genetic alterations in chromosome 11 in embryonal and alveolar rhabdomyosarcoma].
    Brinkschmidt C; Poremba C; Schäfer KL; Simon R; Jürgens H; Böcker W; Dockhorn-Dworniczak B
    Verh Dtsch Ges Pathol; 1998; 82():210-4. PubMed ID: 10095436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
    Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosomal and genetic imbalances in Chinese patients with rhabdomyosarcoma detected by high-resolution array comparative genomic hybridization.
    Liu C; Li D; Hu J; Jiang J; Zhang W; Chen Y; Cui X; Qi Y; Zou H; Zhang W; Li F
    Int J Clin Exp Pathol; 2014; 7(2):690-8. PubMed ID: 24551291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics.
    Grass B; Wachtel M; Behnke S; Leuschner I; Niggli FK; Schäfer BW
    Histopathology; 2009 Jun; 54(7):873-9. PubMed ID: 19469909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry.
    Dehner CA; Rudzinski ER; Davis JL
    Hum Pathol; 2024 May; 147():72-81. PubMed ID: 38135061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advantage of FISH analysis using FKHR probes for an adjunct to diagnosis of rhabdomyosarcomas.
    Matsumura T; Yamaguchi T; Seki K; Shimoda T; Wada T; Yamashita T; Hasegawa T
    Virchows Arch; 2008 Mar; 452(3):251-8. PubMed ID: 18094995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.
    Ragazzini P; Gamberi G; Pazzaglia L; Serra M; Magagnoli G; Ponticelli F; Ferrari C; Ghinelli C; Alberghini M; Bertoni F; Picci P; Benassi MS
    Histol Histopathol; 2004 Apr; 19(2):401-11. PubMed ID: 15024701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.